ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Bayer will acquire cell-therapy developer BlueRock

by Michael McCoy
August 9, 2019 | APPEARED IN VOLUME 97, ISSUE 32

 

Bayer will acquire full control of the cell-therapy developer BlueRock Therapeutics in a deal that values the company at up to $1 billion. Bayer and Versant Ventures established BlueRock in 2016 to develop regenerative medicines based on induced pluripotent stem cells (iPSCs). Bayer is now buying Versant’s 59% stake. Bayer recently committed $215 million to Century Therapeutics, another Versant-backed iPSC firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment